This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Aug 2011

Enobia Raises $40M for Hypophosphatasia Candidate Development

Data from the study in juveniles confirmed therapy using ENB-0040 led to significant improvements in rickets in treated patients.

Enobia Pharma raised $40 million in a private placement to fund further development of its Phase II-stage enzyme replacement therapy (ERT) ENB-0040 for the genetic bone disorder hypophosphatasia.


Enobia was in addition recently awarded a $1.2 million, three-year FDA orphan grant to support development of ENB-0040 for the long-term treatment of infants and young children with hypophosphatasia.


The genetic bone disorder hypophosphatasia is caused by deficiency in a tissue-nonspecific form of alkaline phosphatase (TNSALP), and causes inorganic pyrophosphate to accumulate in the extracellular space and inhibit skeletal mineralization, leading to rickets in pediatric patients and osteomalacia in adults.


Related News